HOME >> BIOLOGY >> NEWS
Enzyme mimetic reduces tissue damage in colitis animal study

ings, or fistulas, develop in the intestine. Because of difficulty diagnosing the disease, the estimated incidence of these disorders varies widely. Crohns disease, however, is now considered to be the second most common chronic inflammatory disorder, after rheumatoid arthritis.

In the study, researchers evaluated the effects of M40403 on inflammatory bowel disease and symptoms. Comparing treated animals to untreated animals:

Colonic tissue damage, as evaluated histologically, was substantially reduced.

Inflammation was reduced, as confirmed by a significant increase in both colon and spleen weights.

TNF-a and IL-1b levels were reduced to near normal.

Adhesion molecule expression in the intestinal wall was reduced.

Diarrhea and body weight loss were markedly reduced.

The results of this study echo those from another MetaPhore study looking at rheumatoid arthritis published this month in Arthritis & Rheumatism. In that study, an SOD mimetic was highly effective, not only at treating inflammation, but also preventing joint damage and reducing elevated cytokine levels to near normal in animal models of arthritis. These preclinical findings bode well for the potential of SOD mimetics as clinical candidates for inflammatory bowel disease, including Crohns disease and ulcerative colitis, said Daniela Salvemini, Ph.D., MetaPhores Vice President of Pharmacology and the principal investigator. The protective effects observed in this model appear to be a result of the SOD mimetics ability to inhibit superoxide and cytokine production, consistent with earlier research and our recent positive preclinical outcomes in models of arthritis.


'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
12-Dec-2001


Page: 1 2

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Enzyme activation appears key in helping internal clock tell night from day
3. Enzyme fully degrades mad cow disease prion
4. Enzyme revealed that is key to funguss ability to breach immune system
5. Enzyme discovery sheds light on causes of rare disease, cancer
6. Enzyme could overcome industrial bleaching waste problems
7. Enzyme controls good cholesterol
8. Enzyme discovery to benefit homeland security, industry
9. Enzyme could aid cancer fight
10. Enzyme once thought harmful to Alzheimers patients now appears key to future treatment
11. Enzyme studies at Brookhaven Lab may lead to new antiviral agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... ... 04, 2019 , ... Molecular Devices, a global leader in ... new President of Molecular Devices, replacing Greg Milosevich who has been appointed President ... Since joining Molecular Devices in a scientific engineering role, Ms. Murphy has held ...
(Date:6/1/2019)... ... May 31, 2019 , ... The ... Rosati recently invested in BioFactura’s $6M Series B Financing Round. , “With ... institutional investors who bring significant financial and business resources to bear as we ...
(Date:5/31/2019)... ... May 31, 2019 , ... The OilComm Conference ... TX, announced today that Ben Reiter, Senior Writer at Sports Illustrated and Author ... 3rd.     , Reiter predicted the Houston Astros would win the MLB championship in ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... (PRWEB) , ... June 11, 2019 , ... ... of Personalized Stem Cells Inc. (PSC) , has announced that their GMP ... Health, Food and Drug Branch for manufacturing. This is an important milestone ...
(Date:6/6/2019)... ... June 05, 2019 , ... WCCT Global, Inc ., a full-service ... today that they will be receiving 3 awards at the 2019 CRO Leadership Awards, ... awards in the categories of overall Quality and Compatibility (Access to desired markets, cultural ...
(Date:5/31/2019)... Redwood City, California (PRWEB) , ... ... ... received allowance of our patent applications from the USPTO providing proprietary interest ... SYSTEM AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP ...
(Date:5/31/2019)... NEWPORT BEACH, Calif. (PRWEB) , ... May 30, ... ... the future of neurotoxins, is pleased to announce the strategic acquisition of Metabiologics, ... for research. The acquisition provides Object exclusive ownership and commercialization rights to a ...
Breaking Biology Technology:
Cached News: